Overview

Optimizing Pazopanib Exposure in RCC Patients

Status:
Terminated
Trial end date:
2016-03-22
Target enrollment:
Participant gender:
Summary
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
Phase:
Phase 2
Details
Lead Sponsor:
Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Collaborator:
OnkoDataMed GmbH